Initial positive results reported on vaccine to treat genital herpes

Posted under: Health and Medicine , News Releases , Research , Science , Technology. Initial, positive results were reported today, Sept. 12,  on a therapeutic vaccine candidate for treating patients with genital herpes. This first-in-class, investigational, protein subunit vaccine, GEN-003, is under development by Genocea Biosciences, Inc. Dr. Anna Wald, University of Washington professor of medicine and laboratory medicine in the School of Medicine and professor of epidemiology in the School of Public Health, is among those leading clinical studies of GEN-003. The trials are also taking place at six other centers in the United States. One of several components of the vaccine was designed at the UW in Dr. David Koelle's lab in the Division of Allergy and Infectious Diseases, Department of Medicine.
account creation

TO READ THIS ARTICLE, CREATE YOUR ACCOUNT

And extend your reading, free of charge and with no commitment.

Register


Login

Your Benefits

  • Access to all content
  • Receive newsmails for news and jobs
  • Post ads

myScience